透析依赖性肾衰竭的血糖管理与个体化糖尿病照护
本文综述透析依赖性肾衰竭合并糖尿病患者的血糖管理。美国近60万透析患者中超过60%合并糖尿病,其总体生存率和心血管生存率均低于无糖尿病者。肾衰竭相关因素使糖化血红蛋白(HbA1c)目标难以外推,缺乏前瞻性研究确定最佳血糖目标,降糖药物随机临床试验极少纳入透析患者。观察性数据显示较低和较高HbA1c均与透析人群死亡率相关,现有数据提示部分降糖药在透析人群可能安全有效,但受研究设计和样本量限制无法得出确切结论。
要点
- 美国近60万透析患者中超过60%合并糖尿病,其总体和心血管生存率均低于无糖尿病者。
- 肾衰竭相关因素使HbA1c目标难以外推至透析人群,且无前瞻性研究确立最佳血糖目标。
- 观察性数据显示较低和较高HbA1c均与透析人群死亡率相关,但研究设计及样本量限制确切结论。
核心结论
- 肾衰竭相关因素使HbA1c目标外推至透析人群不可靠,并可能改变降糖及疾病修饰治疗的风险获益特征。
- 无前瞻性研究确立透析人群最佳血糖目标,降糖药物随机临床试验极少纳入透析患者。
- 观察性数据显示较低和较高HbA1c均与透析人群死亡率相关。
- 现有数据提示部分降糖药在透析人群可能安全有效,但研究设计和样本量限制妨碍确切结论。
- 人群特异性知识缺口不应削弱为透析患者提供以人为中心糖尿病照护的重要性。
研究设计与样本
- 本文为综述,未报告系统检索范围。
- 原文未报告样本量。
主要发现
- 美国近60万接受透析的慢性肾衰竭患者中超过60%合并糖尿病。
- 接受透析的糖尿病患者总体生存率和心血管生存率均低于无糖尿病者。
- 观察性数据显示较低和较高HbA1c均与透析人群死亡率相关。
- 部分降糖药在透析人群可能安全有效,但确切结论受研究设计和样本量限制。
关键数值与推荐
- 透析依赖性糖尿病患者的照护应整体化,基于个体偏好和预后,并将已验证对血糖控制和心血管风险降低有益的治疗方法与个体化照护相整合。
- 原文未报告具体血糖目标阈值、药物剂量或推荐等级。
临床怎么用
- 原文未据此给出具体推荐。
- 作者认为,人群特异性知识缺口不应削弱为透析患者提供以人为中心糖尿病照护的重要性。
- 作者认为,透析依赖性糖尿病患者的照护应整体化,基于个体偏好和预后,并整合已验证有益的治疗方法。
- 作者认为,需额外研究以了解近期药理学和技术进展如何支持透析患者的个体化照护。
局限性
- 无前瞻性研究确立透析人群最佳血糖目标。
- 降糖药物随机临床试验极少纳入透析患者。
- 现有数据受研究设计和样本量限制,无法得出确切结论。
- 人群特异性知识缺口妨碍将所有普通人群糖尿病指南扩展至透析依赖性糖尿病群体。
- 需额外研究以了解药理学和技术进展如何支持透析患者的个体化照护。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Of the nearly 600,000 people in the U.S. who receive dialysis for chronic kidney failure, >60% have diabetes. People receiving dialysis who have diabetes have worse overall and cardiovascular survival rates than those without diabetes. Diabetes care in the dialysis setting is complicated by kidney failure-related factors that render extrapolation of glycated hemoglobin (HbA1c) targets to the dialysis population unreliable and may change the risk-benefit profiles of glucose-lowering and disease-modifying therapies. No prospective studies have established the optimal glycemic targets in the dialysis population, and few randomized clinical trials of glucose-lowering medications included individuals receiving dialysis. Observational data suggest that both lower and higher HbA1c are associated with mortality in the dialysis population. Existing data suggest the potential for safety and effectiveness of some glucose-lowering medications in the dialysis population, but firm conclusions are hindered by limitations in study design and sample size. While population-specific knowledge gaps about optimal glycemic targets and diabetes medication safety and effectiveness preclude the extension of all general population diabetes guidelines to the dialysis-dependent diabetes population, these uncertainties should not detract from the importance of providing person-centered diabetes care to people receiving dialysis. Diabetes care for individuals with and without dialysis-dependent kidney failure should be holistic, based on individual preferences and prognoses, and tailored to integrate established treatment approaches with proven benefits for glycemic control and cardiovascular risk reduction. Additional research is needed to inform how recent pharmacologic and technological advances can be applied to support such individualized care for people receiving maintenance dialysis.
引用
- Klein KR, Lingvay I, Tuttle KR, et al. Glycemic Management and Individualized Diabetes Care in Dialysis-Dependent Kidney Failure. Diabetes Care. 2025. PMID: 39693267. doi:10.2337/dci24-0081
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。